APA (7th ed.) Citation

KG, D., MM, M., MT, M., MA, H., BDE, D., KA, C., . . . CR, D. (2026). Pharmacy-level barriers to opioid overdose prevention: Availability and accessibility of naloxone and buprenorphine-naloxone in high-risk Texas counties. Harm reduction journal, 23(1), . https://doi.org/10.1186/s12954-026-01441-x

Chicago Style (17th ed.) Citation

KG, Darouiche, Malik MM, Mohr MT, Hagenimana MA, Digbeu BDE, Cunningham KA, Farr NM, and Dostal CR. "Pharmacy-level Barriers to Opioid Overdose Prevention: Availability and Accessibility of Naloxone and Buprenorphine-naloxone in High-risk Texas Counties." Harm Reduction Journal 23, no. 1 (2026). https://doi.org/10.1186/s12954-026-01441-x.

MLA (9th ed.) Citation

KG, Darouiche, et al. "Pharmacy-level Barriers to Opioid Overdose Prevention: Availability and Accessibility of Naloxone and Buprenorphine-naloxone in High-risk Texas Counties." Harm Reduction Journal, vol. 23, no. 1, 2026, https://doi.org/10.1186/s12954-026-01441-x.